Icosapent ethyl approved for cardiovascular risk reduction
The Food and Drug Administration’s decision on reduction of events in high-risk patients was based primarily on the REDUCE-IT trial results.
Related Articles
The language of AI and its applications in health care
AI can make clinical care more efficient; however, many find its confusing terminology to be a barrier.
Trauma epidemiology and the organization of trauma care in the US
Patients who are injured do better when treated at trauma centers.
On thoughtful selection of medications in the acute critical care setting
As critical care medicine advances understanding of ICU survivorship, thoughtful selection of medications is needed.
Atypical pulmonary cysts: Why to care
ACR updated its Lung-RADS to include atypical pulmonary cysts in 2022; there has been little discussion on its impact.
Top reads from the CHEST journal portfolio
Studying endotypes in sleep apnea, diagnostic testing in ILD, and inhaled corticosteroid use in children.
On 5 Ps: PSG, PM, PPG, PulseOx, and PAT
OSA has been increasingly recognized and studied, but still many patients remain undiagnosed and untreated.
APPs and POCUS: Overcoming credentialing challenges
APPs play an integral role in the care and management of patients in the ICU and across the spectrum of health care.
Changing the tumor board conversation: Immunotherapy in resectable NSCLC
Immunotherapy has transformed the treatment landscape of NSCLC and enhanced survival rates.
Expanding recommendations for RSV vaccination
Respiratory syncytial virus (RSV) has been increasingly recognized as a prevalent cause of lower respiratory tract infection (LRTI) among adults in the United States.
Short telomere length and immunosuppression: Updates in nonidiopathic pulmonary fibrosis, interstitial lung disease
Interstitial lung diseases (ILDs) are a diverse group of relentlessly progressive fibroinflammatory disorders.